Medical Cannabinoids UK: Laws, Prescriptions, Research and Patient Safety
An educational guide to cannabis-based medicines in the United Kingdom, including THC, CBD, licensed treatments, prescribing regulations, clinical evidence and important health considerations.
Updated: October 2026
What Are Medical Cannabinoids?
Medical cannabinoids are cannabinoid substances used or investigated for therapeutic purposes. Cannabinoids are compounds that interact with biological signalling systems, including the endocannabinoid system.
Some cannabinoids occur naturally in cannabis plants, while others can be manufactured synthetically. Their chemical structures, biological activities and potential clinical applications differ.
The best-known plant-derived cannabinoids include tetrahydrocannabinol (THC) and cannabidiol (CBD). Although these substances come from the same general plant family, they should not be treated as interchangeable.
THC can cause intoxication and impairment. CBD does not typically produce the same intoxicating effects, although it can still cause adverse effects and interact with medicines.
In the United Kingdom, the term "medical cannabis" generally describes cannabis-based products used for medicinal purposes. However, not every cannabis-containing product is a legally recognised medicine.
Medical Cannabinoids and the Endocannabinoid System
The endocannabinoid system is a biological signalling network involved in several physiological processes.
It includes cannabinoid receptors, naturally occurring signalling molecules called endocannabinoids, and enzymes that participate in their production and breakdown.
CB1 Receptors
CB1 receptors are found in several parts of the nervous system. They are involved in signalling processes associated with functions such as memory, movement, appetite and pain perception.
CB2 Receptors
CB2 receptors are associated particularly with immune-system activity, although their distribution and functions are more complex than a simple division between brain and immune cells.
Why This Matters for Medicine
Understanding cannabinoid signalling helps researchers investigate how particular compounds might influence specific symptoms or biological processes.
However, a plausible biological mechanism does not establish that a substance is an effective treatment. Clinical evidence is required to determine whether potential benefits outweigh risks for a particular condition.
THC vs CBD in Medical Research
THC and CBD differ in their pharmacology, adverse-effect profiles and regulatory considerations.
| Feature | THC | CBD |
|---|---|---|
| Full name | Tetrahydrocannabinol | Cannabidiol |
| Intoxicating effects | Can cause intoxication | Not typically intoxicating |
| UK controlled-drug status | Controlled cannabinoid | Pure CBD is not itself controlled |
| Clinical research | Investigated for selected medical indications | Investigated for epilepsy and other conditions |
| Safety considerations | Impairment, psychological effects and interactions | Side effects, liver-related concerns and interactions |
The clinical significance of a cannabinoid depends on the specific medicine, condition, available evidence and individual patient.
For a more detailed scientific comparison, read our educational article: THC vs CBD: Understanding the Differences.
Are Medical Cannabinoids Legal in the UK?
In November 2018, UK legislation was amended to permit the prescribing of certain cannabis-based products for medicinal use under defined conditions.
This reform established a legal medical framework. It did not legalise recreational cannabis or remove the controls applying to THC and other controlled substances.
The rules distinguish between regulated medicines, qualifying cannabis-based products for medicinal use and ordinary commercial cannabis products.
A product marketed using terms such as "medical grade", "therapeutic" or "cannabinoid wellness" does not automatically qualify as a medicine.
Official guidance is available from the UK Home Office.
Who Can Prescribe Medical Cannabis in the UK?
Prescribing rules depend on the medicine's classification and licensing status.
For most unlicensed cannabis-based products for medicinal use, the initial prescription must be made by a doctor on the General Medical Council's Specialist Register with an appropriate clinical interest.
Different rules apply to certain licensed medicines, including specific preparations such as nabilone and THC:CBD spray.
NICE guidance also describes circumstances in which subsequent prescribing may take place through an appropriate shared-care arrangement.
The central principle is that prescribing should involve clinical assessment, consideration of available evidence, monitoring and informed decision-making.
Licensed and Unlicensed Cannabis-Based Medicines
One of the most important distinctions in UK medical cannabis regulation is the difference between licensed medicines and unlicensed preparations.
Licensed Medicines
A licensed medicine has received regulatory authorisation for specified uses based on an assessment of quality, safety and efficacy.
The authorisation does not mean that the medicine is suitable for every condition or patient. Its approved indications and prescribing information remain important.
Unlicensed Medicines
An unlicensed medicine does not have the same marketing authorisation for the relevant preparation. In certain circumstances, clinicians may prescribe unlicensed medicines to meet an individual patient's special clinical needs.
Such decisions require professional judgement and appropriate clinical safeguards.
Important Distinction
"Unlicensed medicine" does not mean the same thing as an illegally supplied recreational product.
The medical prescribing framework contains specific requirements that distinguish legitimate clinical use from unauthorised commercial supply.
Examples of Cannabinoid-Based Medicines
Epidyolex
Epidyolex contains cannabidiol and is authorised for particular severe epilepsy syndromes. Its use is governed by specific clinical indications and prescribing recommendations.
Sativex
Sativex is a prescription oromucosal spray containing THC and CBD.
NICE recommends it under defined conditions for moderate to severe spasticity associated with multiple sclerosis when other treatments have not provided adequate relief.
Nabilone
Nabilone is a synthetic cannabinoid medicine.
NICE advises that it may be considered as an additional treatment for adults experiencing persistent chemotherapy-related nausea and vomiting despite optimised conventional treatment.
These examples illustrate why medical cannabinoid discussions must focus on particular medicines and clinical indications rather than making broad claims about cannabis as a whole.
Medical Cannabinoids and Epilepsy
One of the best-established areas of clinical cannabinoid research concerns certain severe epilepsy syndromes.
Specific cannabidiol medicines have demonstrated benefits in defined patient populations under controlled clinical conditions.
This evidence does not establish that ordinary CBD products or recreational cannabis can treat epilepsy.
Prescribing decisions require specialist assessment, careful monitoring and consideration of interactions with other anti-seizure medicines.
Medical Cannabinoids and Multiple Sclerosis
Multiple sclerosis is a condition affecting the central nervous system. Some people experience spasticity, which can involve muscle stiffness and involuntary spasms.
NICE provides specific recommendations for THC:CBD spray in selected adults with moderate to severe spasticity where other pharmacological treatments have not been effective.
Treatment is initiated and supervised by an appropriately experienced specialist.
The existence of this recommendation does not mean that all cannabis products are effective treatments for multiple sclerosis.
Medical Cannabinoids and Chemotherapy-Related Nausea
Chemotherapy can cause nausea and vomiting, sometimes despite standard antiemetic treatment.
NICE recommends considering nabilone as an additional treatment in certain adults when symptoms persist despite optimised conventional medicines.
This recommendation is specific to a defined clinical situation. It should not be interpreted as a general endorsement of cannabis products for all forms of nausea.
Medical Cannabinoids and Chronic Pain
Chronic pain is frequently discussed in relation to medical cannabis, but the clinical evidence remains complex and contested.
NICE guideline NG144 recommends against offering THC, nabilone, dronabinol or THC:CBD combinations for chronic pain in adults. It also recommends against offering CBD for chronic pain outside a clinical trial.
These recommendations reflect the evidence assessed by NICE and should not be confused with individual patient reports or commercial advertising claims.
Research continues, but uncertainty about effectiveness, long-term safety and comparative benefit remains important.
Potential Side Effects and Medical Risks
Cannabinoid-based medicines can cause adverse effects. The nature and likelihood of these effects depend on the medicine and the individual.
Psychological Effects
THC-containing preparations may cause anxiety, confusion, changes in mood and other psychological effects.
Impairment and Sedation
Some cannabinoid medicines can cause drowsiness, dizziness or impaired coordination.
Medicine Interactions
Cannabinoids can interact with other medicines, including some medicines affecting the central nervous system.
Dependence and Misuse
THC-containing products may present risks of dependence and misuse. These concerns form part of clinical risk assessment.
Pregnancy and Breastfeeding
Cannabinoid exposure during pregnancy and breastfeeding raises important safety concerns. Professional medical guidance is essential.
Why Clinical Monitoring Matters
Monitoring helps healthcare professionals assess whether a prescribed treatment is providing the intended benefit and whether adverse effects are occurring.
NICE advises clinicians to consider medical history, mental health, other medicines, potential dependence and relevant physical conditions.
Clinical records can also help improve understanding of outcomes and adverse events associated with cannabis-based medicines.
Evidence Before Claims
The medical potential of a cannabinoid must be assessed through reliable clinical research.
A promising laboratory result, anecdotal report or advertising claim is not equivalent to demonstrated clinical effectiveness.
Medical Cannabis vs Commercial Cannabis Products
Commercial cannabis products and prescribed cannabinoid medicines should not be treated as interchangeable.
Legitimate medicines are subject to defined clinical and regulatory requirements. Online product listings may not provide equivalent assurances about composition, safety or legal status.
The NHS warns that cannabis-based products advertised online may have uncertain contents and may be unlawful or unsafe.
Readers can also explore our related educational overview: Medical Weed UK: Understanding the Legal Framework.
Common Misunderstandings About Medical Cannabinoids
Myth: Medical Cannabis Is Legal for Everyone
UK law permits certain medical uses under defined conditions. It does not authorise unrestricted possession or supply of cannabis.
Myth: CBD Products Are All Medicines
CBD may appear in medicines and other product categories. A commercial CBD product does not automatically have a medicinal authorisation.
Myth: Natural Products Have No Side Effects
Plant-derived compounds can cause adverse effects and interact with medicines.
Myth: Every Cannabis Product Has the Same Effects
Cannabinoid composition, formulation and individual patient characteristics can affect outcomes.
Myth: Medical Cannabis Is Proven for Every Condition
Clinical evidence varies substantially between different conditions.
Frequently Asked Questions
Are medical cannabinoids legal in the UK?
Certain cannabinoid-based medicines can be legally prescribed under UK regulations. Recreational cannabis remains controlled.
Is medical cannabis available on the NHS?
Certain cannabis-based medicines may be prescribed on the NHS for specific clinical indications. Access is limited and depends on specialist assessment.
Are THC and CBD the same?
No. They are different cannabinoids with distinct effects and regulatory considerations.
Can medical cannabinoids treat epilepsy?
Certain licensed cannabidiol medicines are used for specific severe epilepsy syndromes. This does not establish that all cannabis products treat epilepsy.
Are cannabinoid medicines suitable for chronic pain?
NICE does not recommend the listed cannabis-based medicinal products for routine management of chronic pain in adults.
Are all medical cannabis products licensed?
No. UK medical practice distinguishes between licensed medicines and certain unlicensed preparations prescribed under specific rules.
Can cannabinoid medicines interact with other medication?
Yes. Potential interactions are an important consideration during clinical assessment.
Is CBD always legal in the UK?
Pure CBD is not itself a controlled drug, but finished products may be subject to other rules, including restrictions relating to controlled cannabinoids.
Conclusion
Medical cannabinoids represent an important but carefully regulated area of modern medicine.
The UK permits certain cannabis-based medicines under specific prescribing and regulatory conditions. However, evidence of benefit varies considerably by medicine and clinical indication.
Patients and readers should distinguish between licensed medicines, specialist-prescribed unlicensed products and ordinary commercial cannabis products.
Reliable medical information should come from qualified healthcare professionals and authoritative organisations such as the NHS, NICE and UK medicines regulators.